Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 2/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29418904 | 1.00 | CYP4F2 (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL23546535 | 0.91 | RXRA (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL23043733 | 0.89 | CYP4F2 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL25795327 | 0.88 | RXRA (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL31127775 | 0.88 | RXRA (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21379111 | 0.88 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21243880 | 0.88 | CYP4F2 (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29592576 | 0.88 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL31527219 | 0.87 | RXRA (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL24802911 | 0.87 | RXRA (0.34) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12624033-B2 | KRAS inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250250271-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250154148-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-05-15 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | BIOMEA FUSION, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
| WO-2021211864-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| EP-3749665-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2019155399-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CYP4F2 3406/4885CYP4A11 1064/4885RXRA 4205/4885 |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | TOP2A, TOP1, TOP2B | CYP4F2 579/4885CYP4A11 1687/4885RXRA 4159/4885 |
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | KRAS, NRAS, TP53 | CYP4F2 4657/4885CYP4A11 4349/4885RXRA 2045/4885 |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | TOP2A, TOP1, TOP2B | CYP4F2 579/4885CYP4A11 1687/4885RXRA 4159/4885 |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | CYP4F2 2561/4885CYP4A11 1528/4885RXRA 2831/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CYP4F2 2828/4885CYP4A11 2524/4885RXRA 3260/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | CYP4F2 4690/4885CYP4A11 4627/4885RXRA 3326/4885 |
| US-20250154148-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP4F2 4675/4885CYP4A11 4085/4885RXRA 3532/4885 |
| US-20250250271-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP4F2 4675/4885CYP4A11 4085/4885RXRA 3532/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP4F2 4223/4885CYP4A11 1434/4885RXRA 3298/4885 |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP4F2 2545/4885CYP4A11 2241/4885RXRA 3493/4885 |
| US-12624033-B2 | KRAS inhibitors | KRAS, NRAS, BRAF | CYP4F2 4423/4885CYP4A11 3994/4885RXRA 4744/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CYP4F2 3182/4885CYP4A11 991/4885RXRA 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.